Biological activities of a human pluripotent hemopoietic colony stimulating factor on normal and leukemic cells.
E Platzer(Friedrich-Alexander-Universität Erlangen-Nürnberg), M A Moore(Memorial Sloan Kettering Cancer Center), Li Lu(Second Affiliated Hospital of Xi'an Jiaotong University), Paul E. Harris(Flow Pharma (United States)), Roland Mertelsmann(Unknown), Janice Gabrilove(Memorial Sloan Kettering Cancer Center), Karl Welte(University Children's Hospital Tübingen)
Cited by 171
Related Papers
Recombinant Human Granulocyte Colony-Stimulating Factor: Effects on Normal and Leukemic Myeloid Cells
|Science|1986|1.2k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor.
|Proceedings of the National Academy of Sciences|1985|522
Epidemiology of non-Hodgkin?s lymphoma (NHL): trends, geographic distribution, and etiology
|Annals of Hematology|2004|488